α-Methyl-DL-tryptophan

α-Methyl-DL-tryptophan (α-Methyltryptophan), a tryptophan derivative, is a selective SLC6A14 blocker. In estrogen receptor (ER) -positive breast cancer cells, α-Methyl-DL-tryptophan inhibits mTOR and activates autophagy and apoptosis. α-Methyl-DL-tryptophan also has the effect of reducing weight[1][2].

Product Specifications

CAS Number

[153-91-3]

Product Name Alternative

α-Methyltryptophan

UNSPSC

12352209

Hazard Statement

H302, H312, H332

Target

Amino Acid Derivatives; Apoptosis; Autophagy; mTOR

Type

Peptides

Related Pathways

Apoptosis; Autophagy; Others; PI3K/Akt/mTOR

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/α-methyl-dl-tryptophan.html

Purity

99.92

Solubility

DMSO : 8.33 mg/mL (ultrasonic; warming; heat to 60°C) |Ethanol : 10 mg/mL (ultrasonic)

Smiles

CC(CC1=CNC2=CC=CC=C12)(C(=O)O)N

Molecular Formula

C12H14N2O2

Molecular Weight

218.26

Precautions

H302, H312, H332

References & Citations

[1]Karunakaran S, et al. SLC6A14 (ATB0, +) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer. J Biol Chem. 2011 Sep 9;286 (36) :31830-8. |[2]Sathish Sivaprakasam, et al. α-Methyl-l-tryptophan as a weight-loss agent in multiple models of obesity in mice. Biochem J. 2021 Apr 16;478 (7) :1347-1358.